• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Inhibikase Therapeutics Inc (NQ: IKT )

    1.560 +0.080 (+5.41%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Jul 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 39,200
    Open 1.510
    Bid (Size) 1.500 (4)
    Ask (Size) 1.560 (4)
    Prev. Close 1.480
    Today's Range 1.440 - 1.610
    52wk Range 0.7900 - 3.820
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
    Company expects to report trial results in 4Q24 
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
    From Inhibikase Therapeutics
    Via GlobeNewswire

    Performance

    YTD
    +17.13%
    +17.13%
    1 Month
    +17.29%
    +17.29%
    3 Month
    +13.87%
    +13.87%
    6 Month
    -10.34%
    -10.34%
    1 Year
    -40.00%
    -40.00%

    More News

    Read More
    Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
    From Inhibikase Therapeutics
    Via GlobeNewswire
    IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024
    Via InvestorPlace
    Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
    From Inhibikase Therapeutics
    Via GlobeNewswire
    IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q4 2023
    Via InvestorPlace
    Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
    From Inhibikase Therapeutics
    Via GlobeNewswire
    HC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To Know
    Via Benzinga
    Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Dr. Milton Werner, CEO of Inhibikase Therapeutics, Inc. is Featured in an Interview With SmallCapsDaily
    Via NewMediaWire
    Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
    Via AB Newswire
    Topics Retirement
    Exposures Pension
    Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
    From Inhibikase Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
    From Inhibikase Therapeutics
    Via GlobeNewswire
    Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.